PURPOSE The combination of zanubrutinib plus obinutuzumab was found to be well tolerated with an early signal of efficacy in a phase 1b study. ROSEWOOD is a phase II, randomized study that assessed the efficacy and safety of zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL). METHODS Patients with R/R FL who had received ≥2 lines of therapy, including an anti-CD20 antibody and an alkylating agent, were randomized 2:1 to receive zanubrutinib plus obinutuzumab (ZO) or obinutuzumab (O). The primary endpoint was overall response rate (ORR) by independent central review (ICR). Secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival, and safety. RESULTS A total of 217 patients were randomized (ZO: 145; O: 72). Median study follow-up was 20.2 months. The study met its primary endpoint: ORR by ICR was 69% (ZO) versus 46% (O; P = .001). Complete response rate was 39% (ZO) versus 19% (O); 18-month DOR rate was 69% (ZO) versus 42% (O). Median PFS was 28.0 months (ZO) versus 10.4 months (O; hazard ratio, 0.50 [95% CI, 0.33 to 0.75], P < .001). The most common adverse events with ZO were thrombocytopenia, neutropenia, diarrhea, and fatigue; incidences of atrial fibrillation and major hemorrhage were 3% and 1%, respectively. CONCLUSION The combination of ZO met its primary endpoint of a superior ORR versus O, and demonstrated meaningful activity and a manageable safety profile in patients with R/R FL. ZO had a favorable benefit-risk profile compared with O, and represents a potential combination therapy for patients with R/R FL.